Ascendis Pharma A/S (ASND) DCF Valuation
- ✓ Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
- ✓ Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
- ✓ Pré-Construits Pour Une Utilisation Rapide Et Efficace
- ✓ Aucune Expertise N'Est Requise; Facile À Suivre
Ascendis Pharma A/S (ASND) Bundle
Evaluate Ascendis Pharma A/S's financial outlook like an expert! This (ASND) DCF Calculator comes with pre-loaded financials and offers total flexibility to modify revenue growth, WACC, margins, and other critical assumptions to align with your projections.
Discounted Cash Flow (DCF) - (USD MM)
Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
---|---|---|---|---|---|---|---|---|---|---|
Revenue | 13.9 | 7.2 | 8.1 | 53.3 | 277.6 | 391.4 | 551.7 | 777.7 | 1,096.2 | 1,545.3 |
Revenue Growth, % | 0 | -48.01 | 11.87 | 557.93 | 421.2 | 40.96 | 40.96 | 40.96 | 40.96 | 40.96 |
EBITDA | -225.9 | -342.4 | -441.0 | -578.8 | -428.0 | -391.4 | -551.7 | -777.7 | -1,096.2 | -1,545.3 |
EBITDA, % | -1622.65 | -4730.1 | -5447 | -1086.57 | -154.16 | -100 | -100 | -100 | -100 | -100 |
Depreciation | 6.9 | 9.2 | 16.7 | 18.4 | 19.7 | 228.1 | 321.5 | 453.2 | 638.9 | 900.6 |
Depreciation, % | 49.86 | 126.6 | 205.77 | 34.46 | 7.09 | 58.28 | 58.28 | 58.28 | 58.28 | 58.28 |
EBIT | -232.9 | -351.5 | -457.7 | -597.2 | -447.7 | -391.4 | -551.7 | -777.7 | -1,096.2 | -1,545.3 |
EBIT, % | -1672.51 | -4856.7 | -5652.78 | -1121.03 | -161.25 | -100 | -100 | -100 | -100 | -100 |
Total Cash | 622.6 | 748.2 | 710.0 | 765.6 | 415.8 | 391.4 | 551.7 | 777.7 | 1,096.2 | 1,545.3 |
Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Account Receivables | .8 | .4 | 2.3 | 12.4 | 58.1 | 65.8 | 92.7 | 130.7 | 184.3 | 259.8 |
Account Receivables, % | 6.01 | 5.57 | 28.28 | 23.27 | 20.91 | 16.81 | 16.81 | 16.81 | 16.81 | 16.81 |
Inventories | .0 | .0 | 78.5 | 136.0 | 217.5 | 217.9 | 307.1 | 432.9 | 610.2 | 860.2 |
Inventories, % | -0.000022429907 | 0.000014382281 | 969.47 | 255.35 | 78.33 | 55.67 | 55.67 | 55.67 | 55.67 | 55.67 |
Accounts Payable | 28.9 | 22.8 | 61.9 | 105.2 | 98.4 | 340.9 | 480.5 | 677.3 | 954.7 | 1,345.8 |
Accounts Payable, % | 207.59 | 314.93 | 763.91 | 197.43 | 35.46 | 87.09 | 87.09 | 87.09 | 87.09 | 87.09 |
Capital Expenditure | -5.4 | -22.4 | -25.2 | -15.1 | -2.5 | -209.6 | -295.5 | -416.5 | -587.1 | -827.7 |
Capital Expenditure, % | -38.57 | -309.97 | -311.57 | -28.31 | -0.91557 | -53.56 | -53.56 | -53.56 | -53.56 | -53.56 |
Tax Rate, % | -1.54 | -1.54 | -1.54 | -1.54 | -1.54 | -1.54 | -1.54 | -1.54 | -1.54 | -1.54 |
EBITAT | -232.6 | -351.3 | -457.2 | -602.7 | -454.6 | -391.2 | -551.4 | -777.3 | -1,095.7 | -1,544.5 |
Depreciation | ||||||||||
Changes in Account Receivables | ||||||||||
Changes in Inventories | ||||||||||
Changes in Accounts Payable | ||||||||||
Capital Expenditure | ||||||||||
UFCF | -203.0 | -370.3 | -507.1 | -623.8 | -571.3 | -138.4 | -501.9 | -707.5 | -997.4 | -1,405.9 |
WACC, % | 7.48 | 7.48 | 7.48 | 7.48 | 7.48 | 7.48 | 7.48 | 7.48 | 7.48 | 7.48 |
PV UFCF | ||||||||||
SUM PV UFCF | -2,860.6 | |||||||||
Long Term Growth Rate, % | 2.00 | |||||||||
Free cash flow (T + 1) | -1,434 | |||||||||
Terminal Value | -26,163 | |||||||||
Present Terminal Value | -18,240 | |||||||||
Enterprise Value | -21,101 | |||||||||
Net Debt | 262 | |||||||||
Equity Value | -21,364 | |||||||||
Diluted Shares Outstanding, MM | 56 | |||||||||
Equity Value Per Share | -379.55 |
What You Will Receive
- Pre-Filled Financial Model: Ascendis Pharma A/S's actual data facilitates accurate DCF valuation.
- Comprehensive Forecast Control: Modify revenue growth, profit margins, WACC, and other essential drivers.
- Real-Time Calculations: Automatic updates allow you to view results instantly as you make adjustments.
- Investor-Ready Template: A polished Excel file crafted for high-quality valuation presentations.
- Customizable and Reusable: Designed for adaptability, enabling repeated use for in-depth forecasts.
Key Features
- Comprehensive Financial Data: Ascendis Pharma A/S's (ASND) historical financial statements and pre-filled projections.
- Customizable Parameters: Adjust WACC, tax rates, revenue growth, and EBITDA margins to fit your analysis.
- Real-Time Insights: Monitor Ascendis Pharma A/S's (ASND) intrinsic value as it recalculates instantly.
- Intuitive Visualizations: Dashboard charts illustrate valuation outcomes and essential metrics clearly.
- Designed for Precision: A professional-grade tool tailored for analysts, investors, and finance professionals.
How It Works
- Download the Template: Gain immediate access to the Excel-based ASND DCF Calculator.
- Input Your Assumptions: Modify the yellow-highlighted cells for growth rates, WACC, margins, and other key variables.
- Instant Calculations: The model automatically recalculates Ascendis Pharma’s intrinsic value.
- Test Scenarios: Experiment with various assumptions to see how they impact valuation outcomes.
- Analyze and Decide: Utilize the findings to inform your investment or financial assessment.
Why Choose This Calculator for Ascendis Pharma A/S (ASND)?
- Accurate Data: Up-to-date Ascendis Pharma financials provide dependable valuation insights.
- Customizable: Tailor key inputs such as growth rates, WACC, and tax rates to fit your forecasts.
- Time-Saving: Pre-configured calculations save you the hassle of starting from the ground up.
- Professional-Grade Tool: Crafted for investors, analysts, and consultants in the biotech sector.
- User-Friendly: Easy-to-navigate design and clear instructions cater to users of all experience levels.
Who Should Use This Product?
- Investors: Accurately assess Ascendis Pharma A/S’s (ASND) fair value prior to making investment choices.
- CFOs: Utilize a high-quality DCF model for financial reporting and analysis related to Ascendis Pharma A/S (ASND).
- Consultants: Easily customize the template for valuation reports tailored to clients interested in Ascendis Pharma A/S (ASND).
- Entrepreneurs: Acquire knowledge about financial modeling practices employed by leading biotech firms like Ascendis Pharma A/S (ASND).
- Educators: Implement it as a teaching resource to illustrate valuation techniques applicable to companies like Ascendis Pharma A/S (ASND).
What the Template Contains
- Historical Data: Includes Ascendis Pharma A/S’s past financials and baseline forecasts.
- DCF and Levered DCF Models: Detailed templates to calculate Ascendis Pharma A/S’s intrinsic value.
- WACC Sheet: Pre-built calculations for Weighted Average Cost of Capital.
- Editable Inputs: Modify key drivers like growth rates, EBITDA %, and CAPEX assumptions.
- Quarterly and Annual Statements: A complete breakdown of Ascendis Pharma A/S’s financials.
- Interactive Dashboard: Visualize valuation results and projections dynamically.